In order for our site to display correctly you will need a newer version of your web browser.
The following browsers support numerous web standards including CSS, XHTML, and the DOM (a universal means of controlling the behavior of web pages):
- Netscape v7 or higher (all platforms), Mozilla FireFox (Windows), Camino (Mac OS X), Galeon (Linux GNOME Desktop) or other browser stemming from the Mozilla.org project.
- Opera v7 or higher (Windows, Linux)
- Apple's Safari (Mac OS X)
- Konqueror (Linux KDE Desktop)
- Microsoft Internet Explorer v6 or higher (Windows) or v5 or higher (Macintosh)
Please note that this is not intended be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Finding Cures. Saving Children.
The Power of a Legacy
Over 50 years ago, my father, Danny Thomas, embarked on the journey of a lifetime… the quest to fulfill his promise to St. Jude Thaddeus by building a place where the most helpless and hopeless among us – children facing cancer – could turn in their time of greatest need.
And today, because of your generous support, St. Jude Children’s Research Hospital stands as a tangible testament to the power of a legacy.
Eliza Leatherman
Meet St. Jude Patient Eliza Leatherman
Once upon a time, Eliza Leatherman’s future seemed anything but certain…
In January 1993, Eliza, then just 2 years old, developed a cough that no antibiotic could cure. A CT scan finally revealed to her parents, Ann and Bobby, the terrible truth that an enormous tumor had developed in their darling child’s chest. The tumor was so large, in fact, that doctors were unable to see her rib cage.
A Gift of Stock for the Kids of St. JudeMike Corboy finds that making gifts using long-held stock that has increased in value is a wonderful way to benefit the kids of St. Jude.
- Read More about Mike
- Learn More about Appreciated Securities
- St. Jude finds mechanism for faulty protein disposal
A discovery by St. Jude scientists offers new insights into how myeloma cells dispose of defective or excess proteins. This finding could lead to new cancer treatments.
